Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?

Published:2019-02-01 Issue:1 Volume:9 Page:
ISSN:2110-5820
Container-title:Annals of Intensive Care
language:en
Short-container-title:Ann. Intensive Care

Author:

Lemiale Virginie, ,Meert Anne-Pascale,Vincent François,Darmon Michael,Bauer Philippe R.,Van de Louw Andry,Azoulay Elie

Publisher

Springer Science and Business Media LLC

Subject

Critical Care and Intensive Care Medicine

Link

http://link.springer.com/article/10.1186/s13613-019-0487-x/fulltext.html

Reference95 articles.

1. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10.

2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. Longo DL, éditeur. N Engl J Med. 2018;378(2):15868.

3. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(17):1627–39.

4. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–32.

5. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123–35.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Performances of preoperative CT scan to predict the pTN stage for MSI/dMMR localized colon cancers;ESMO Open;2024-08

2. Elucidating CTLA-4’s role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments;Molecular Diversity;2024-07-10

3. Association between specific human leukocyte antigen alleles and development of thyroid immune-related adverse event;Immunotherapy;2024-06-18

4. Management and outcome of oncological patients under immune checkpoint inhibitors presenting at the emergency department;Emergency Medicine Journal;2024-04-30

5. Hypophysitis Induced by Sintilimab in the Treatment of Bladder Cancer: A Case Report;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3